MetaCap

Atrium Therapeutics Inc. (RNA)

NASDAQ: RNAHealth CareBiotechnology: Pharmaceutical PreparationsUSD

6.92-0.06 (-0.86%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

RNA stock chart

Technical analysis

Key statistics

All statistics
Market cap
$149.27M
EPS (TTM)
-$5.22
52-week range
6.36 – 16.77
Day range
6.88 – 7.44
Volume / Avg
319.59K / 297.20K
Beta
—

52-week range

$6.36$16.77

RNA stock today

Atrium Therapeutics (RNA) closed at $6.92 on Nov 20, down 0.86% (-$0.06), versus the S&P 500's 3.70% decline. Shares are 58.7% below their 52-week high of $16.77, set on Mar 5, 2026 and 8.8% above the 52-week low of $6.36, near the bottom of the past year's range. Atrium Therapeutics has posted a net loss over the last twelve months (EPS of -$5.22), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Atrium Therapeutics

Company profile

Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipeline to treat a range of genetic and cardiac diseases.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Ms. Kathleen P. Gallagher
Headquarters
San Diego, CA

Analyst forecast

Forecast

Consensus (5 analysts)

strong_buy

Avg. price target

$22.00+217.92%

  • Strong buy 0
  • Buy 5
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $15.00High $25.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 12, 2026
EPS actual vs est.
$-0.25 vs $-1.15
Surprise
+78.26%

RNA news

All RNA news

Atrium Therapeutics peers

Health Care sector
RNA peer companies
CompanyPrice% ChgMarket capCompare
ELDNEledon Pharmaceuticals Inc.1.78-6.32%$150.34Mvs RNA
IFRXInflaRx N.V.1.04-4.59%$153.26Mvs RNA
VRXAVeraxa Biotech AG1.04+0.97%$147.06Mvs RNA
PRQRProQR Therapeutics N.V.1.04-0.95%$146.98Mvs RNA
ORMPOramed Pharmaceuticals Inc.3.57-3.25%$155.24Mvs RNA
BBOTBridgeBio Oncology Therapeutics Inc.1.81-2.69%$145.25Mvs RNA
EMISEmmis Acquisition Corp. Class A10.36+0.15%$163.36Mvs RNA
ALXOALX Oncology Holdings Inc.1.06+3.92%$137.03Mvs RNA

Indexes, lists and sector

Atrium Therapeutics stock FAQ

What is Atrium Therapeutics's stock price today?

RNA last traded at $6.92 as of Nov 20, 4:00 PM EST, down 0.86% on the day. Prices are delayed at least 15 minutes.

Who is Atrium Therapeutics's CEO?

Ms. Kathleen P. Gallagher is the chief executive officer of Atrium Therapeutics Inc..

What is the RNA 52-week high?

The 52-week high for RNA is $16.77 and the 52-week low is $6.36. The stock is currently 58.7% below its high.

Compare RNA